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Background/aim: The prognostic values of systemic inflammatory markers, neutrophil to lymphocyte ratio (NLR), and platelet to
lymphocyte ratio (PLR) on overall survival (OS) of metastatic renal cell carcinoma patients (mRCC) treated with tyrosine kinase
inhibitors (TKI) remain unclear. Thus, the present study aimed to investigate the prognostic impact of these markers on OS of mRCC
patients.
Materials and methods: A total of 150 patients receiving TKIs were retrospectively analyzed. Progression-free survival and OS times
were analyzed with the Kaplan–Meier method, and the log‐rank test was used for comparison. Univariable and multivariable Cox
regression models evaluated the impact of NLR and PLR on OS of the patients. The receiver operating characteristic curve analysis
determined that the optimal cut-off values of NL, and PLR in predicting OS were 2 and 204, respectively.
Results: Patient with PLR > 204 had significantly lower median OS time than those with PLR ≤ 204 (14.6 months vs. 31.6 months, P
< 0.001). While the univariate analyses showed that both NLR and PLR associated with OS (NLR: P = 0.002; PLR: P < 0.001), PLR,
not NLR, was an independent determinant for OS in the multivariate analyses (Hazard Ratio: 2.535, 95% CI: 1.564-4.108, P < 0.001).
Additionally, the presence of brain metastases and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
prognostic scoring system were identified as independent prognostic factors for OS (brain metastases: P = 0.040; IMDC: P < 0.001).
Conclusion: The PLR is a readily and inexpensively obtained marker, which may predict OS in patients with mRCC treated with TKIs.
Key words: NLR, PLR, metastatic renal cell carcinoma, prognosis, tyrosine kinase inhibitors

1. Introduction
Renal cell carcinoma (RCC) is one of the most commonly
seen malignancies, accounting for almost 4% of oncological
disease burden [1]. Distant metastases have been detected
in %20-30 of patients with RCC at the presentation [2].
Tyrosine kinase inhibitors (TKI), including sunitinib or
pazopanib, are widely used first-line treatment options for
metastatic renal cell carcinoma (mRCC) patients, targeting
the vascular structure of RCC [3]. Heng et al. published the
most commonly used current prognostic scoring system,
which included hemoglobin count, neutrophil count,
platelet count, corrected serum calcium level, Karnofsky
performance status, and time to treatment initiation < 1
year, to provide individualized patient care and clinical
trials development [4]. According to the International
Metastatic Renal Cell Carcinoma Database Consortium
(IMDC), the treatment options of patients with mRCC are

individualized [5]. However, it seems rational to add new
prognostic determinants to this scoring system for better
prognostication and treatment of patients with mRCC.
RCC has been evaluated as a highly immune-infiltrated
tumor harboring a plenteous amount of infiltrating
lymphocytes [6]. It was shown that clear cell RCC has
the highest cell based on a T cell infiltration score and
an immune infiltration score among the 19 cancer types
analyzed by The Cancer Genome Atlas research program
[7]. The determinants of a systemic inflammatory response,
such as neutrophil to lymphocyte ratio (NLR), platelet to
lymphocyte ratio (PLR), and the Glasgow prognostic score
were suggested as independent predictors for survival
outcomes in various types of solid tumors, including
RCC. However, taking the studies conducted with NLR
and PLR levels into consideration, there are conflicting
findings. In patients with mRCC, Gunduz et al. found
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no significant association between the PLR and OS, but
Park et al. showed PLR as a significant indicator for both
progression-free survival (PFS) and overall survival [8, 9].
Furthermore, while Pichler et al. demonstrated that NLR
was not a significant predictor for cancer-specific survival
in patients with RCC (HR: 1.59, P = 0.148), Keizman et al
found that low NLR levels are associated with better OS.
(HR: 0.3, P = 0.043) [10,11]. Thus, in the present study, we
aimed to provide further knowledge about the prognostic
impact of the systemic inflammatory markers, NLR and
PLR, on OS in patients with mRCC receiving TKIs.
2. Materials and methods
2.1. Patients
A total of 150 consecutive patients with mRCC treated
with TKIs between 2008 and 2019 at the Department Of
Medical Oncology Unit of a Tertiary-Care Cancer Center
were enrolled in the present retrospective-observational
cohort study. The whole cohort was composed of patients
with pathologically confirmed mRCC of any subtype,
and those treated with TKIs (Pazopanib, and sunitinib)
until progression, death, or unacceptable side effect. All
the patients had cytokine treatment before initiation of
TKIs. Patients who had an acute or chronic infection,
autoimmune, and hematological diseases, chronic
liver, renal diseases, and those receiving drugs were not
included in the present study as these histories can affect
the parameters measured in the complete blood count.
The including patients had complete blood count data
within 7 days before the initiation of TKIs, pazopanib,
or sunitinib. Patients were stratified in three risk groups
according to the IMDC scoring system (Favorable risk: no
risk factor; intermediate risk: 1–2 risk factor; poor risk: >
3 risk factor). The demographic and clinicopathological
characteristics variables of patients used in the study were
gathered from our center’s electronic records. The study
approval was obtained from the local ethics committee and
all procedures in the present study have been conducted
following the 1964 Helsinki declaration, and its later
amendments.
2.2. Statistical analysis
Continuous variables were presented as median and
interquartile range, and dichotomous variables were
presented as percentages. Mann–Whitney U and Chisquare tests were used for comparison of continuous
and categorical variables in the independent groups,
respectively. NLR and PLR were calculated as the division
of the absolute neutrophil count to the absolute lymphocyte
count for NLR and division of the absolute platelet count to
the absolute lymphocyte count for PLR. PFS was measured
from the initiation of TKIs until progression and/or death.
OS was measured from the initiation of TKIs until the last
follow-up and/or death. Kaplan–Meier method was used
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for survival analyses, and a long-rank test was done to
compare the differences between prognostic subgroups.
The receiver operator characteristics (ROC) curves with
Youden’s J index were plotted to determine the optimal
cut-off values of NLR and PLR in predicting OS. The
univariate and multivariate analyses were conducted using
Cox proportional hazards regression models to define
risk factors for OS. Multivariate analyses were performed
using the variables with a P value of ≤ 0.25 in the
univariate analyses. The statistical analyses in the present
study were done using SPSS v25 (IBM Inc., Armonk, NY,
USA) software, and a P < 0.05 was regarded as statistically
significant.
3. Results
3.1. Patient characteristics stratified according to PLR
values
Baseline demographic, clinical, histopathological
characteristics of the patients stratified according to PLR
values were summarized in Table 1. A total of 150 patients
(male/female: 114/36) with a median age of 60 years, who
were treated with TKIs for mRCC were enrolled after the
exclusion of patient with acute or chronic infection (n =
8), autoimmune diseases (n = 2), hematological diseases
(n = 6), chronic liver (n = 5), renal diseases (n = 6), and
those with lost to follow up (n = 25). Completeness of the
retrospectively collected data was 97% for histological
subtype, 90% for tumor grade, and there was no
missing data for remaining demographic and clinical
parameters. Later lines of treatment choices included
axitinib, everolimus, and nivolumab. Histologically, our
study population was mostly composed of patients with
clear cell RCC (78.5%). According to the IMDC scoring
system, while more than half the patients were evaluated
in the intermediate-risk group (57.3%), the percentages of
patients with favorable, and poor-risk groups were 15.3%
and 27.3%, respectively. By applying the ROC analysis, the
NLR value of 2 was evaluated as the optimal cut-off point
(AUC: 0.67; sensitivity: 63%; specificity: 77%, P = 0.0001),
and PLR value of 204 evaluated as the optimal optimal cutoff point in predicting OS (AUC: 0.66; sensitivity: 46%;
specificity: 84%, P = 0.0004) (Figure 1). While PLR values
were not found statistically different between favorable
and intermediate-risk group (Median PLR: 143 vs 141,
respectively), the poor-risk group had significantly higher
PLR values than the favorable and intermediate-risk group
(Median PLR: 152, P < 0.001) (Figure 2).
3.2. The prognostic significance of NLR, and PLR for OS
Ninety-three (%62) patients died within the median
follow-up time of 18 months (minimum-maximum:
1.3–72.8). The measured PFS and OS times of the whole
population were 11 months (95% CI: 8.4–13.5), and 22.3
months (95% CI: 18.3–26.4). When we stratified the
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Table 1. Baseline patient characteristics stratified according to PLR cut-off.
Characteristics

Low PLR (≤ 204; n = 98)

Age (years)
Sex (%)
Female
Male
Histology (%)
Clear cell
Non-clear cell
Lung metastasis (%)
Yes
No
Liver metastasis (%)
Yes
No
Bone metastasis (%)
Yes
No
Brain metastasis (%)
Yes
No
Tumor grade (%)
Grade I- II
Grade III-IV
IMDC risk group (%)
Favorable
Intermediate
Poor
Treatment type (%)
Pazopanib
Sunitinib
Second line treatment
Axitinib
Everolimus
Nivolumab
None
Third line treatment
Axitinib
Everolimus
Nivolumab
None
Forth line treatment
Axitinib
Everolimus
Nivolumab
None
OS (months)

59 (53–64)

High PLR (> 204; n = 52)
61 (52–67)

P value
0.235

23.1
76.9

33.9
66.1

0.135

80.8
19.2

75.9
24.1

0.463

76
24

74.6
25.4

0.843

18.3
81.7

30.5
69.5

0.073

19.2
80.8

35.6
64.4

0.021

4.8
95.2

3.4
96.6

1

32.3
67.7

26.4
73.6

0.676

18.3
65.4
16.3

6.8
50.8
42.4

65.4
34.6

72.9
27.1

18.4
19.4
20.4
41.8

23.1
25
21.2
30.8

18.4
3.1
7.1
71.4

17.3
5.8
3.8
73.1

3.1
2
3
91.8
31.6

3.8
1.9
94.2
14.6

0.001
0.324

0.576

0.759

0.955
< 0.001

Continuous variables were given as median with interquartile range. Dichotomous variables were given as percentages. IMDC:
International Metastatic Renal Cell Carcinoma Database Consortium, OS: Overall survival.

patients according to the IMDC scoring system, while the
median OS time of patients with the favorable-risk group
was not reached, on continuing follow-up, the median
OS time of the patients with intermediate and poor-risk
group was 25.7 months (95% CI: 20–31.4) and 9.6 months
(95% CI: 5.9–13.3), respectively (Figure 3). Kaplan–Meier
curves demonstrated that patients with higher NLR or
PLR had significantly inferior OS times than those with

lower NLR or PLR (NLR: 17.4 months vs. 27.9 months,
P = 0.002; PLR: 14.6 months vs. 31.6 months, P < 0.001)
(Figure 4A for NLR, Figure 4B for PLR). Taking the 3-year
Kaplan–Meier estimate of survival into consideration,
the survival rates of patients with higher or lower NLR
and higher or lower PLR were 23% and 46% for NLR,
while 3% and 50% for PLR, respectively. The presence of
bone metastasis (P = 0.017), liver metastasis (P = 0.037),
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Figure 1. ROC curve showed that the PLR value of 204 was the optimal cut-off
in predicting OS.

Figure 2. PLR values in IMDC subgroups.
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Figure 3. Kaplan–Meier estimates of OS in patients stratified according to IMDC risk groups.

Figure 4. Kaplan-Meier estimates of OS in patients stratified according to NLR (A), and PLR (B) cut-off values.

NLR > 2 (P = 0.002), PLR > 204 (P < 0.001), and IMDC
scoring system (P < 0.001) were determined as significant
prognosticators for shortened OS by the univariate Cox
analysis (Table 2). However, multivariate Cox analyses, as
shown in Table 3, PLR > 204, not NLR, were independent
indicators in predicting OS (HR: 2.535, 95% CI: 1.564 4.108, P < 0.001). In addition to PLR, the other identified
independent factors for OS were the presence of brain
metastases (HR: 2.512, 95% CI: 1.041 - 6.066, P = 0.040)
and the IMDC scoring system (P < 0.001).

4. Discussion
TKIs sunitinib and pazopanib are included in the firstline treatment options in patients with mRCC. However,
it remains unclear which patient will respond better to
the treatment. It seems quite necessary to develop new
prognostic determinants to achieve better prognostic
scoring system(s) because of the achievement of the
insufficient concordance indexes of IMDC (0.74 to 0.82 for
PFS; 0.68 to 0.89 for OS) [12]. There are emerging pieces
of evidence that the markers of systemic inflammatory
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Table 2. Univariate analyses demonstrating the associations between the variables and OS.
Variables

HR
Lower

Upper

Age

1.012

0.994

1.030

0.198

reference
0.862

0.542

1.373

reference
0.463
0.466
0.646

0.533
0.418

0.107
0.110
0.154

2.007
1.972
2.706

0.303
0.299
0.358

reference
0.990

0.590

1.661

0.969

reference
1.937

1.268

2.960

0.002

reference
3.591

2.314

5.570

< 0.001

reference
0.897

0.552

1.460

0.660

reference
1.645

1.031

2.625

0.037

reference
1.716

1.099

2.680

0.017

reference
1.740

0.756

4.099

reference
2.338
8.105

0.193
< 0.001

1.053
3.543

5.188
18.539

0.037
< 0.001

Sex
Male
Female
Tumor grade
Grade I
Grade II
Grade III
Grade IV
Histology
Clear cell
Nonclear cell
NLR
≤2
>2
PLR
≤ 204
> 204
Lung metastases
Absent
Present
Liver metastases
Absent
Present
Bone metastasis
Absent
Present
Brain metastasis
Absent
Present
IMDC risk group
Favorable
Intermediate
Poor

95% CI for HR

P value

NLR: Neutrophil to lymphocyte ratio, PLR: Platelet to lymphocyte ratio, IMDC: International Metastatic Renal Cell Carcinoma Database
Consortium.

response including NLR and PLR may have a potential
role in predicting OS of mRCC patients treated with TKIs.
Our study revealed that while PLR > 204 was associated
with OS shortening, NLR was not found as an independent
predictor of OS.
NLR is an indicator of systemic inflammation response.
Increased local and systemic response to tumor is associated
with high NLR, which facilitates tumor invasion and
metastasis by providing a suitable microenviroment [13].
Tumor-associated macrophages coming from monocytes
have a role in resistance to antivascular endothelial growth
factor (VEGF) directed therapy by causing neutrophilia
via interleukin-6 secretion [14]. Lymphocytopenia and
the depression of cell-mediated immunity caused by the
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chemokines and cytokines are other charecteristics of
systemic inflammatory response [15]. It was reported that
RCC with a Von Hippel-Lindau (VHL) mutation results
in declined T lymphocyte count [16]. High NLR was
shown to be associated with inferior outcomes in mRCC
patients treated with TKIs in previous studies, and cutoff values of NLR ranged from 2 to 4 [17–19]. Our study
showed that NLR value of 2 was the optimal cut-off point
in predicting OS. However, NLR was not found as an
independent predictor for OS in our multivariate analyses.
The conflicting cut-off points in these studies may have
resulted from the fact that the composition of histology
(clear cell/non clear cell) and IMDC risk score groups may
be different from one study to another.
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Table 3. Multivariate analyses identifying the independent risk factors for prediction of OS.
Variables

HR

Age
Liver metastases
Absent
Present

1.012

Bone metastasis
Absent
Present
Brain metastasis
Absent
Present
NLR
≤2
>2
PLR
≤ 204
> 204
IMDC risk group
Favorable
Intermediate
Poor

reference
1.157
reference
1.279

95% CI for HR

P value

Lower

Upper

0.994

1.030

0.198

0.706

1.896

0.563

0.796

2.056

0.309
0.040

reference
2.512

1.041

6.066

reference
1.274

0.811

2

0.294

reference
2.535

1.564

4.108

< 0.001

reference
2.117
5.873

0.944
2.460

4.748
14.020

0.069
< 0.001

NLR: Neutrophil to lymphocyte ratio, PLR: Platelet to lymphocyte ratio, IMDC: International Metastatic Renal Cell Carcinoma Database
Consortium

The elevated PLR has been shown as an independent
determinant for survival outcomes of patients with
diversified types of cancer including the most common
ones. Wang et al. demonstrated that PLR is associated
with poorer survival outcomes in patients with lung
adenosquamous cancer (P = 0.001) [20]. PLR, not NLR,
was found as an independent indicator in prediction for
OS of patients with resectable colon cancer (HR: 1.97; P =
0.021) [21]. Krenn-Pilko et al. identified that breast cancer
patients with elevated PLR had shortened OS than those
with decreased PLR (HR: 1.92; P = 0.047) [22]. However,
the exact impact of PLR on survival outcomes of RCC
remains inconsistent. In the study conducted by Gunduz
et al., they evaluated only the association between PLR,
not NLR, survival outcomes of 100 mRCC patients, and
showed that PLR was an independent predictor for PFS but
not for OS (P = 0.029) [8]. However, Chrom et al. found
that NLR ≥ 4, not PLR, was an independent predictor for
OS (P < 0.001) [19]. In contrast to these findings, Park et
al. analyzed the prognostic value of NLR and PLR along
with the documented prognostic determinants in 63
mRCC patients treated with TKIs, and PLR > 150, not
NLR, was associated with OS in their multivariate analyses
(HR: 16.1; P = 0.001) [9]. Similar to the study by Park et
al., we showed that PLR was an independent predictor for
OS, and no significant association between NLR and OS

was determined. The conflicting findings in these studies
may have resulted from the inadequate measurement of
the cut-off points by ROC analysis in one study than in
the another. Furthermore, these cohort studies may be
composed of heterogeneous patient populations who were
stratified according to IMDC prognostic scoring systems.
The exact underlying influence mechanisms of altered
PLR remain unclear. The study by Lu et al. revealed that
chronic inflammation may take part in tumor formation
and progression [23]. While RCC has an immunogenic
nature, there is an inadequate knowledge in the literature
about the roles of inflammatory pathways and immune
cells in progression and immune escape mechanisms of
RCC. VHL, a tumor suppressor gene, is involved in the
carcinogenesis process of the vast majority of the patients
with clear cell RCC [24]. Inactivated VHL results in an
increased amount of hypoxia-inducible factor (HIF),
which plays a role in the transcription of key genes related
to tumor survival, including vascular endothelial growth
factor (VEGF) [25]. HIF may take part in the creation
of a tumor microenvironment rich in myeloid cells,
neutrophils, and macrophages by stimulating chemokine
production [26]. Increased interleukin-8 (IL-8) levels have
been detected in serum samples of RCC cases, and IL-8
may influence the amount of neutrophil and platelet counts
[27]. Thrombocytosis is a well-known predictor for worse
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oncologic outcomes in renal cell carcinoma [28]. VEGF,
platelet-derived growth factor, hepatocyte growth factor,
thrombospondins, and endostatin are secreted molecules
from platelets, and they have a key role in angiogenesis
and carcinogenesis process [29]. It was suggested that
thrombocytosis participates in the progression of RCC
by causing elevated interleukin-6 levels, which result in a
sustained T helper type 2 cytokine response via stimulating
macrophages and T-lymphocytes [30,31]. Lymphocytes
are involved in the immune response of the host against
the tumor, and it was shown that direct connection
between tumor-infiltrating lymphocytes and tumor cells
resulted in the cytolysis of tumor cells, diminished tumor
burden, and create superior survival outcomes [32,33].
Nevertheless, it remains necessary to explain the exact
association between the tumor cell and lymphocytes and
platelets by future trials.
The limitations of the present study include the
retrospective nature of the study conducted at a single
center. However, NLR and PLR were separately evaluated
in predicting OS in most studies mentioned above. We

analyzed the impact of both markers on OS with a relatively
larger study population than the studies that were aimed to
investigate the prognostic value of these markers in mRCC
patients treated with TKIs. Furthermore, since our study
mostly include patients with intermediate-risk (57.3%),
future studies are needed to evaluate the prognostic role of
PLR on mRCC in more homogeneous populations.
In summary, our results revealed that PLR > 204, the
presence of brain metastases, and IMDC scoring system
were independent prognostic determinants in predicting
OS of mRCC patients treated with TKIs. To create more
accurate prognostication and better-personalized treatment
in patients with mRCC, PLR might give an additive value
to the current prognostic scoring system (IMDC).
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